Potentially Resectable MET-altered Non-Small Cell Lung Cancer

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Potentially Resectable MET-altered Non-Small Cell Lung Cancer trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

Not Yet RecruitingPhase 2

NCT06644313

Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

According to the 2024 edition of the NCCN guidelines and the 2023 edition of the CSCO guidelines, perioperative treatment is recommended for patients with stage…

Location not specified31 participantsStarted 2024-11-01

Treatment: Vebreltinib